Replimune Group has seen its share price move sharply in recent years, which naturally puts the spotlight on what the current US$10.86 level really represents. The key issue for you as a shareholder or potential buyer is whether that price still lines up with what the balance sheet and book value can support.

• Replimune Group is up 141.3% over the past year, so anyone looking at the stock today has to ask if that kind of move is backed by the assets and equity on the books.

• The business model is highly dependent on ongoing research and development spending, which can affect how much of the company's book value reflects productive assets versus capital that still needs to earn its keep.

• Your read on Replimune Group is one view; the desks covering it have another. See what analysts think Replimune Group's shares could be worth .

The issue now is whether Replimune Group's recent share price level is justified by its book value when compared with the industry average.

If you are weighing Replimune Group against other opportunities that also trade heavily on balance sheet strength and equity value, a focused stock screen is a clean starting point with solid balance sheet and fundamentals stocks screener (25 results) .

Has Replimune Group Run Too Far on Book Value?

P/B is a cleaner lens for Replimune Group because the business is still loss making, so earnings based ratios like P/E are less useful right now. On this measure, the stock trades at a P/B of about 9.7x, which is far above the Biotechs industry average of roughly 1.8x and well ahead of the peer group near 4.5x. That gap points to investors paying a rich price for each dollar of equity on the balance sheet.

Such a premium P/B multiple often reflects strong confidence in the company's research pipeline or future cash generation, rather than what the current financials alone would suggest. It also means the margin for error can be tight if the business does not eventually justify that higher book value multiple. Anyone considering Replimune Group therefore needs to weigh whether the balance sheet and R&D profile are enough to support this elevated reading on P/B. Explore the numbers behind Replimune Group's P/B valuation .

The Replimune Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Replimune Group valuation puzzle leaves off by explaining which expectations for future growth, margins and earnings would need to hold for the shares to trade meaningfully higher or lower than today. Each narrative on Replimune Group's Community page links a specific number back to a clear view on how the business might scale, how profitability could shift and how the risk profile might change as new information comes through.